Ono Pharmaceutical Co., Ltd. (4528.T) Bundle
A Brief History of Ono Pharmaceutical Co., Ltd.
Ono Pharmaceutical Co., Ltd., founded in 1717, is one of Japan's oldest pharmaceutical companies. Initially established as a traditional medicine retailer in Osaka, it has since evolved into a major player in the biopharmaceutical sector. The company transitioned from herbal remedies to modern pharmaceuticals in the 20th century.
In 1955, Ono pioneered the research and development of synthetic pharmaceuticals, marking a significant shift in its business model. The company’s focus sharpened on therapeutic areas such as oncology, immunology, and pain management. By 2000, Ono established its global presence, forming partnerships with international biotech firms.
Ono's flagship product, Opdivo (nivolumab), received approval in Japan in 2014 for the treatment of advanced melanoma. This immuno-oncology drug has been a driving force behind the company's revenue growth. For the fiscal year ending March 2023, Ono reported revenues of approximately ¥313.3 billion (around USD 2.4 billion), primarily attributed to sales of Opdivo and related products.
The following table summarizes Ono Pharmaceutical's key financial data over the past five fiscal years:
| Fiscal Year | Revenue (¥ billion) | Operating Income (¥ billion) | Net Income (¥ billion) | Earnings per Share (¥) |
|---|---|---|---|---|
| 2023 | 313.3 | 55.9 | 44.5 | 124.16 |
| 2022 | 293.4 | 59.8 | 49.1 | 137.19 |
| 2021 | 273.1 | 50.2 | 39.4 | 110.45 |
| 2020 | 236.8 | 42.1 | 31.2 | 87.84 |
| 2019 | 207.7 | 36.4 | 28.5 | 79.16 |
In 2021, Ono entered into a strategic collaboration with Bristol-Myers Squibb to co-develop new immuno-oncology therapies. This partnership highlights Ono's commitment to expanding its pipeline and enhancing its research capabilities.
The company continues to invest heavily in R&D, with expenditures reaching approximately ¥72 billion (around USD 550 million) in 2023, which represents a significant portion of its total operating income. Ono's R&D efforts have also led to the development of other notable products, including Allergan's (now part of AbbVie) Rinvoq and Yervoy.
Ono's stock performance on the Tokyo Stock Exchange has shown resilience, with its shares trading at around ¥5,650 as of October 2023, reflecting a year-to-date increase of approximately 15%. The company's market capitalization stands at about ¥1.4 trillion (approximately USD 10.5 billion).
As of October 2023, the company's workforce comprises approximately 2,500 employees, contributing to its mission of advancing global health through innovative therapies and strong corporate governance.
Overall, Ono Pharmaceutical Co., Ltd. serves as a testament to longevity and adaptability in the ever-evolving pharmaceutical landscape.
A Who Owns Ono Pharmaceutical Co., Ltd.
Ono Pharmaceutical Co., Ltd., a prominent player in the biopharmaceutical industry, has a diverse ownership structure. As of the latest data, the ownership is divided among institutional investors, individual shareholders, and company executives. The company's shares are traded on the Tokyo Stock Exchange under the ticker symbol 4528.
As of the fiscal year ending March 2023, Ono Pharmaceutical reported an ownership composition as follows:
| Ownership Type | Percentage of Ownership | Number of Shares Owned |
|---|---|---|
| Institutional Investors | 40.5% | 140,000,000 |
| Individual Shareholders | 18.5% | 63,000,000 |
| Company Executives and Board Members | 6.2% | 21,500,000 |
| Foreign Investors | 30.8% | 104,000,000 |
Ono's significant institutional investors include major asset management firms and investment funds, which typically conduct thorough analysis before investing. Some of the key institutional stakeholders include:
- Japan Trustee Services Bank, Ltd. - 5.4%
- The Master Trust Bank of Japan, Ltd. - 5.1%
- BlackRock, Inc. - 3.9%
- State Street Corporation - 3.3%
The company also has strategic partnerships with various global pharmaceutical companies that can impact shareholder dynamics. Notably, it collaborates with Bristol-Myers Squibb Company for its cancer product, Opdivo, which has significantly influenced its revenue streams, creating a market cap of approximately ¥700 billion as of October 2023.
In terms of recent financial performance, Ono Pharmaceutical's sales for the fiscal year ending March 2023 reached ¥310 billion, with a net income of ¥50 billion, reflecting a 16% increase from the previous year. Earnings per share (EPS) stood at ¥165.
In the investor community, the dividend yield offered by Ono Pharmaceutical is also noteworthy. It reported a dividend payout of ¥70 per share, translating to a dividend yield of 2.1%.
As of October 2023, Ono Pharmaceutical's stock performance has shown resilience, with a year-to-date increase of 25%, influenced by favorable clinical trial results and approvals for new drugs.
Ono Pharmaceutical Co., Ltd. Mission Statement
Ono Pharmaceutical Co., Ltd., a Japanese pharmaceutical company, has a clear and focused mission statement that revolves around the development and delivery of innovative healthcare solutions to enhance the quality of life for patients. The company emphasizes its commitment to research and development (R&D) as a cornerstone of its operations, investing significantly in new drug discoveries.
As of fiscal year 2022, Ono reported a R&D expenditure of approximately ¥58.3 billion, reflecting a robust commitment to innovation. This investment underlines the company's strategy to facilitate the creation of new therapeutic modalities, particularly in oncology, immunology, and central nervous system diseases.
Ono’s mission also stresses patient-centricity, aiming to meet the unmet medical needs through pioneering therapies. Their most notable product, Opdivo (nivolumab), has generated significant revenue, contributing to a total sales figure of around ¥367.9 billion in 2022, making up a substantial portion of their overall income.
| Year | R&D Expenditure (¥ billion) | Opdivo Sales (¥ billion) | Total Revenue (¥ billion) | Net Income (¥ billion) |
|---|---|---|---|---|
| 2020 | 54.2 | 158.8 | 314.4 | 56.9 |
| 2021 | 52.7 | 202.4 | 327.8 | 63.7 |
| 2022 | 58.3 | 367.9 | 392.1 | 73.8 |
Furthermore, Ono Pharmaceutical aims to expand its global presence through strategic partnerships and collaborations. As of October 2023, partnerships with various biotechnology companies and research institutions have been formed, allowing them to share resources and expertise, which is essential in today’s highly competitive pharmaceutical landscape. This collaborative approach not only enhances research capabilities but also accelerates the delivery of new treatments to market.
The company’s mission also reflects sustainability and ethical responsibility in its business practices, aligning with global healthcare improvement initiatives. The ongoing commitment is evident through various programs aimed at improving access to medications and fostering community health.
In summary, Ono Pharmaceutical Co., Ltd. pursues a mission that combines innovation in drug development with a patient-first approach. The significant financial investments and strategic partnerships reinforce their commitment to addressing critical health challenges globally.
How Ono Pharmaceutical Co., Ltd. Works
Ono Pharmaceutical Co., Ltd. is a research-driven pharmaceutical company based in Japan, focusing on the development of innovative drugs, particularly in immunology, oncology, and central nervous system disorders. Founded in 1717, it has evolved into a significant player within the global pharmaceutical landscape.
As of the fiscal year ending March 31, 2023, Ono reported a total revenue of approximately JPY 345.3 billion, reflecting a year-over-year increase of 8.2%.
Core Business Segments
Ono operates primarily through three key segments:
- Research and Development (R&D): Major investments are directed toward R&D, with expenditures reaching JPY 86.2 billion in FY 2023.
- Manufacturing and Distribution: The company maintains robust manufacturing capabilities, producing both generic and proprietary drugs.
- Sales and Marketing: Ono has a wide-reaching sales force that promotes its flagship products across Japan and in international markets.
Flagship Products
Ono’s product portfolio includes several notable drugs:
- Opdivo (nivolumab): A monoclonal antibody that has generated substantial revenue, accounting for JPY 225 billion in sales during FY 2023.
- Rebif (interferon beta): This Multiple Sclerosis treatment reported sales of approximately JPY 7.5 billion.
- Others: Additional products contributed about JPY 23 billion combined.
Financial Performance Overview
| Financial Metric | FY 2022 | FY 2023 | Change (%) |
|---|---|---|---|
| Total Revenue | JPY 319.5 billion | JPY 345.3 billion | 8.2% |
| Operating Income | JPY 77.2 billion | JPY 84.5 billion | 9.5% |
| Net Income | JPY 64.1 billion | JPY 71.2 billion | 11.0% |
| R&D Expenses | JPY 80.3 billion | JPY 86.2 billion | 7.4% |
Market Strategy
Ono’s global strategy focuses on expanding its presence in key markets such as the United States and Europe. In FY 2023, international sales made up around 30% of total revenue.
Partnerships with other pharmaceutical companies and research organizations enable Ono to diversify its product pipeline and accelerate development timelines. In particular, the licensing agreement with Bristol-Myers Squibb for Opdivo has been pivotal for market penetration.
Stock Performance
Ono Pharmaceutical trades on the Tokyo Stock Exchange under the ticker symbol 4528. As of October 2023, Ono's stock price was approximately JPY 6,500, with a market capitalization of around JPY 2.5 trillion.
Over the past year, Ono's stock has experienced a growth of 15%, outperforming the benchmark Nikkei 225, which grew by 10% during the same period.
The company’s price-to-earnings (P/E) ratio stands at 22.5, suggesting a favorable valuation in comparison to the pharmaceutical industry average of 20.
Future Outlook
Looking ahead, Ono anticipates sustained growth driven by its advancing pipeline of drugs targeting various cancer indications and autoimmune diseases. As of October 2023, Ono has about 15 compounds in late-stage clinical trials, including treatments for lung cancer and rheumatoid arthritis.
The company plans to allocate approximately 25% of its revenue to R&D over the next five years, aiming to bolster its innovation capacity in the competitive pharmaceutical market.
How Ono Pharmaceutical Co., Ltd. Makes Money
Ono Pharmaceutical Co., Ltd., established in 1717, is a significant player in the pharmaceutical industry, generating revenue through a diverse portfolio of prescription medicines, including oncology, immunology, and pain management. The company's revenue model primarily revolves around drug sales, collaborations, and research and development (R&D) activities.
In fiscal year 2022, Ono Pharmaceutical reported a revenue of ¥204.7 billion (approximately $1.85 billion), reflecting an increase of 13.6% from the previous year. The net income for the same period was ¥36.5 billion (about $329 million), which represented a net profit margin of 17.8%.
Key Revenue Streams
- Drug Sales: The primary source of revenue, with several drugs contributing significantly. In 2022, the sales of Oncolytic products accounted for approximately 60% of total revenues.
- Collaborative Agreements: Partnerships with various research institutions and pharmaceutical companies, generating significant licensing fees and milestone payments.
- Research and Development: R&D investments often lead to new drug approvals, significantly increasing market share and revenue potential.
Major Products and Their Contributions
| Drug Name | Indication | 2022 Sales (¥ billion) | Market Share (%) |
|---|---|---|---|
| Opdivo | Oncology | 92.5 | 40 |
| Kyprolis | Multiple Myeloma | 35.2 | 15 |
| Erelzi | Rheumatoid Arthritis | 20.8 | 10 |
| Anti-PD-1 Antibody | Various Cancers | 30.2 | 25 |
The company’s flagship product, Opdivo (Nivolumab), alone contributed approximately 45% of the total earnings in 2022. The strong performance was driven by the drug's approval for multiple indications, including non-small cell lung cancer and melanoma.
Strategic Collaborations
Ono Pharmaceutical has formed several strategic partnerships that bolster its financial performance. A notable collaboration with Bristol-Myers Squibb (BMS) allows Ono to market Opdivo in Japan, leading to shared revenue that significantly adds to Ono's bottom line. In 2022, revenues from this collaboration accounted for approximately ¥50 billion (around $450 million), enhancing their market position.
Research and Development Expenses
Ono invests heavily in R&D to maintain its competitive edge. In 2022, R&D expenses totaled ¥59.7 billion (about $540 million), representing 29.1% of total revenue. The ongoing clinical trials for new therapies are crucial for sustaining long-term growth and revenue generation.
Future Outlook
With an expanding pipeline of products, including therapies targeting autoimmune diseases and new cancer treatments, Ono Pharmaceutical aims to continue enhancing revenue streams. The company's R&D pipeline includes over 20 molecules under development, indicating strong future growth potential.
Market analysts predict that Ono Pharmaceutical's revenue could reach ¥250 billion (approximately $2.3 billion) by 2025, driven by the anticipated success of new product launches and ongoing demand for existing therapies.
Ono Pharmaceutical Co., Ltd. (4528.T) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.